21/09/2017 - 05:59

PharmAust hits milestone in anti-cancer drug reformulation

21/09/2017 - 05:59


Upgrade your subscription to use this feature.

ASX listed biotech Company PharmAust has made significant progress in reformulating its promising anti-cancer drug Monepantel to improve its taste and deliver increased dosages of the substance in each pill. Monepantel has already shown pleasing results in initial clinical trials as a cancer treatment in humans and canines, with further tests of the drug planned for 2018.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options